<DOC>
	<DOCNO>NCT02653989</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety MDV9300 patient relapse refractory diffuse large B-cell lymphoma ( DLBCL ) achieve either stable disease partial remission follow definitive salvage therapy . Two cohort patient enrol : cohort treat salvage chemotherapy consider ineligible autologous stem cell transplant ( ASCT ) , cohort patient receive ASCT follow salvage chemotherapy .</brief_summary>
	<brief_title>Efficacy Safety Study MDV9300 Patients With Relapsed Refractory Diffuse Large B-cell Lymphoma ( DLBCL )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<criteria>Age 18 year old willing able provide inform consent ; Histologically confirm relapsed refractory CD20+ DLBCL , transform indolent lymphoma ( follicular ) , primary mediastinal large Bcell lymphoma ; Received prior treatment standard anthracycline therapeutic antiCD20 monoclonal antibodybased regimen ; For transplantineligible patient , salvage therapy prior MDV9300 treatment must result PR stable disease ; For post autologous stem cell transplant ( ASCT ) patient , salvage therapy plus ASCT prior MDV9300 treatment must result PR stable disease ; Adequate bone marrow reserve define per protocol ; Eastern Cooperative Oncology Group ( ECOG ) performance status â‰¤ 1 . Patients stable ECOG score 2 may allow medical monitor approval . Burkitt , mantle cell , follicular , mucosaassociated lymphoid tissue lymphoma History serious autoimmune disease ; History central nervous system involvement lymphoma ; Prior therapy agent target immune coinhibitory receptor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>